Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study to Assess the Rate of Pathological Complete Response in Patients With Primary Inflammatory HER2-Positive Breast Cancer Treated With Avastin + Herceptin Based Chemotherapy

Trial Profile

An Open Label Study to Assess the Rate of Pathological Complete Response in Patients With Primary Inflammatory HER2-Positive Breast Cancer Treated With Avastin + Herceptin Based Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Inflammatory breast cancer
  • Focus Therapeutic Use
  • Acronyms BEVERLY2
  • Sponsors Roche
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Aug 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2014 to 1 Oct 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top